Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes.

Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes.

Publication date: Apr 11, 2019

Healthcare expenditures in the United States are growing at an alarming level with the Centers for Medicare and Medicaid Services (CMS) projecting that they will reach $5.7 trillion per year by 2026. Inflammatory diseases and related syndromes are growing in prevalence among Western societies. This growing population that affects close to 60 million people in the U.S. places a significant burden on the healthcare system. Characterized by relatively slow development, these diseases and syndromes prove challenging to diagnose, leading to delayed treatment against the backdrop of inevitable disability progression. Patients require healthcare attention but are initially hidden from clinician’s view by the seemingly generalized, non-specific symptoms. It is imperative to identify and manage these underlying conditions to slow disease progression and reduce the likelihood that costly comorbidities will develop. Enhanced diagnostic criteria coupled with additional technological innovation to identify inflammatory conditions earlier is necessary and in the best interest of all healthcare stakeholders. The current total cost to the U.S. healthcare system is at least $90B dollars annually. Through unique analysis of financial cost drivers, this review identifies opportunities to improve clinical outcomes and help control these disease-related costs by 20% or more.

Wylezinski, L.S., Gray, J.D., Polk, J.B., Harmata, A.J., and Spurlock, C.F. Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes. 17745. 2019 J Clin Med (8):4.

Concepts Keywords
CMS Comorbidity
Comorbidities Ulcerative colitis
Disability Fibromyalgia
Healthcare Irritable bowel syndrome
Imperative Autoimmune diseases
Medicaid Rheumatology
Medicare Abdominal pain
Trillion Medical terminology
RTT
Clinical medicine
Medical specialties
Medicine
Inflammatory conditions
Slow development diseases
Irritable bowel syndrome
Healthcare attention
Burden healthcare system
Interest healthcare

Semantics

Type Source Name
disease DOID ulcerative colitis
disease MESH ulcerative colitis
disease DOID multiple sclerosis
disease MESH multiple sclerosis
disease DOID irritable bowel syndrome
disease MESH irritable bowel syndrome
disease MESH inflammation
disease DOID syndrome
disease DOID fibromyalgia
disease MESH fibromyalgia
gene UNIPROT BEST1
disease MESH comorbidities
disease MESH disease progression
disease MESH development
gene UNIPROT CD2AP
disease MESH Syndromes
disease MESH Diagnosis

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *